GO
Loading...

Enter multiple symbols separated by commas

Regeneron Pharmaceuticals Inc

More

  • Why a FDA nod isn't enough for Regeneron shares Wednesday, 10 Jun 2015 | 12:49 PM ET
    A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, N.Y.

    Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?

  • FDA panel backs first-in-class cholesterol drug Wednesday, 10 Jun 2015 | 8:44 AM ET
    Leonard Schliefer, CEO of Regeneron.

    Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with a caveat.

  • Early movers: TGT, PRU, CL, NFLX, AAPL & more Wednesday, 10 Jun 2015 | 7:51 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • 10 drugs to hit fed budget by $50B over decade Tuesday, 9 Jun 2015 | 1:42 PM ET
    Health Care

    Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.

  • *Wall St banks say September rate hike more likely. Wall Street's top banks said they expect the Fed to begin raising interest rates in September, followed by another increase before the end of the year, according to a Reuters poll. "The market is excited about stronger jobs and higher wages, but before can pop the cork of the champagne bottle, they start thinking...

  • WASHINGTON, June 5- An experimental drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday before a meeting on Tuesday of a panel of outside advisers to the FDA who will discuss...

  • WASHINGTON, June 5- A drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday on the FDA's website before a meeting Tuesday of a panel of outside advisers who will discuss the drug...

  • NEW YORK, June 5- Amazon.com Inc is in a race against Google Inc to store data on human DNA, seeking both bragging rights in helping scientists make new medical discoveries and market share in a business that may be worth $1 billion a year by 2018.. Academic institutions and healthcare companies are picking sides between their cloud computing offerings- Google...

  • Biotech investors up big amid bubble talk Thursday, 28 May 2015 | 9:56 AM ET
    Biotech

    Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • Cramer: Bail out now on this group Wednesday, 20 May 2015 | 6:12 PM ET
    Jet plane

    Jim Cramer was alarmed at what he saw when he looked at transports, especially one group. Time to get out of this group, now.

  • LONDON, May 19- Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Recommendations for marketing approval by its Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

  • Here's how to play weak Q2 earnings season Monday, 18 May 2015 | 7:39 AM ET
    Delta Airlines planes sit at Terminal 4 at John F. Kennedy Airport in New York.

    Negative revenue growth will continue to dog investors in Q2 and Q3, analyst Mike Thompson says. Here's what to do about it.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye drug Eylea to grow even more quickly following data that showed it was superior to rival treatments. Sales of Eylea in the United States leapt 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handsomely beat the average analyst...

  • Early movers: BABA, PCLN, PG, COST, ANN & more Thursday, 7 May 2015 | 7:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye injection Eylea to grow at a faster rate than it had previously forecast. Sales of Eylea in the United States jumped 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handily beat the average analyst estimate by 20 cents.

  • Regeneron profit rises as Eylea sales jump Thursday, 7 May 2015 | 6:39 AM ET

    May 5- Regeneron Pharmaceuticals Inc reported an 11 percent rise in quarterly profit, driven by surging demand for its top-selling eye drug, Eylea. The U.S. biotechnology company's net profit rose to $76 million, or 66 per share, in the first quarter ended March 31, from $68.3 million, or 61 cents per share, a year earlier. Revenue, including collaboration payments...